I.R.C.C.S. Fondazione Santa Lucia

hsantalucia.it

Total trials

54

Active

19

Phase 3

1

Total enrollment

3,046

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 3 of 3 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Terazosin1
Rotigotine 4Mg/24Hrs Patch2
Intra-articular infiltration1

Next readouts

  • 2025-07
  • 2025-11-01
  • 2026-05

Top conditions

  • Stroke14
  • Alzheimer Disease7
  • Multiple Sclerosis7
  • Parkinson Disease5
  • Spinal Cord Injuries4
  • Motor Disorders3
  • Severe Traumatic Brain Injury2
  • Rehabilitation2

Frequently asked questions about I.R.C.C.S. Fondazione Santa Lucia

How many clinical trials does I.R.C.C.S. Fondazione Santa Lucia have on ClinicalTrials.gov?
I.R.C.C.S. Fondazione Santa Lucia is listed as the lead sponsor on 54 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
How many of I.R.C.C.S. Fondazione Santa Lucia's trials are in Phase 3?
1 of I.R.C.C.S. Fondazione Santa Lucia's trials are in Phase 3, spread across 3 active drug programs.
What therapeutic areas does I.R.C.C.S. Fondazione Santa Lucia focus on?
I.R.C.C.S. Fondazione Santa Lucia's most-studied conditions on ClinicalTrials.gov are Stroke, Alzheimer Disease, Multiple Sclerosis, Parkinson Disease, Spinal Cord Injuries.
When are I.R.C.C.S. Fondazione Santa Lucia's next clinical trial readouts?
I.R.C.C.S. Fondazione Santa Lucia has 3 upcoming primary-completion readouts tracked here; the soonest is “A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease”, expected around 2025-07.